Archived research. Equity forecasting is part of the Runchey Research archive (methodology era 1) and is no longer actively updated. Everything remains published at its original URL. Browse the archive
Back to Forecasting
BBIO Forecast Markets
BridgeBio Pharma
7
Active Markets
50%
Avg Probability
All Markets
7 markets
Will the U.S. tafamidis patent proceedings result in at least one Pfizer patent being invalidated by December 31, 2026?
38%
Likely No
94% agreement
Jan 31, 2027
IG: 0.80
Will BridgeBio's Attruby net product revenue exceed $175M in Q1 2026?
68%
Likely Yes
92% agreement
Aug 15, 2026
IG: 0.64
Will Attruby maintain or increase its ATTR-CM NBRx market share above 30% through H1 2026?
58%
Likely Yes
92% agreement
Oct 31, 2026
IG: 0.60
Will BridgeBio file an NDA for encaleret with the FDA by December 31, 2026?
58%
Likely Yes
92% agreement
Jan 31, 2027
IG: 0.56
Will BridgeBio's quarterly cash burn exceed $120M in either Q1 or Q2 2026?
45%
Likely No
94% agreement
Nov 15, 2026
IG: 0.48
Will BridgeBio's SG&A as a percentage of net product revenue decline below 70% by Q4 2026?
53%
Likely Yes
90% agreement
Mar 15, 2027
IG: 0.48
Will BridgeBio announce a share buyback program by December 31, 2026?
29%
Likely No
94% agreement
Jan 31, 2027
IG: 0.40
Resolution Timeline
Oct 31, 2026
Will Attruby maintain or increase its ATTR-CM NBRx market share above 30% through H1 2026?Prediction: 58%
Nov 15, 2026
Will BridgeBio's quarterly cash burn exceed $120M in either Q1 or Q2 2026?Prediction: 45%
Jan 31, 2027
Will BridgeBio file an NDA for encaleret with the FDA by December 31, 2026?Prediction: 58%
Mar 15, 2027
Will BridgeBio's SG&A as a percentage of net product revenue decline below 70% by Q4 2026?Prediction: 53%